Tuesday, October 11, 2011

After strong results in one trial, Alvine readies another Phase II in celiac disease

A small trial by Alvine Pharmaceuticals Inc. indicated that its experimental celiac disease drug may reduce the effect of the intestinal disease, the company said Tuesday.
The 41-patient Phase IIa trial by San Carlos-based Alvine found that certain celiac disease patients taking ALV-003 over six weeks had less severe gluten-induced injury to the lining of their intestine.
Alvine Chief Medical Officer Daniel Adelman said in a press release that the company hopes to start a Phase IIb trial next year.

No comments:

Post a Comment